QUOTE AND NEWS
StreetInsider.com  Apr 15  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Akorn%2C+Inc.+%28AKRX%29+Receives+FTC+Approval+to+Acquire+Hi-Tech+Pharmacal+%28HITK%29/9379628.html for the full story.
newratings.com  Apr 14  Comment 
WASHINGTON (dpa-AFX) - Akorn, Inc. (AKRX) said Monday that the U.S. Federal Trade Commission has voted to approve the company's acquisition of Hi-Tech Pharmacal Co., Inc. (HITK). The unanimous vote in support of the deal follows...
SeekingAlpha  Mar 3  Comment 
Start Time: 10:05 End Time: 11:00 Akorn, Inc. (AKRX) Q4 2013 Earnings Conference Call March 3, 2014 10:00 AM ET Executives Raj Rai – Chief Executive Officer Timothy A. Dick – Chief Financial Officer Analysts ...
TheStreet.com  Mar 3  Comment 
NEW YORK (TheStreet) -- Akorn  was falling 8.75% to $23.56 on Monday after the generic pharmaceutical company issued first-quarter guidance that came up short of analysts' expectations. The company said it expects earnings per share of 76 cents...
Benzinga  Mar 3  Comment 
Akorn (NASDAQ: AKRX) plummeted 11.98% to $22.73 after the company reported Q4 results and issued a weak FY14 guidance. Celldex Therapeutics (NASDAQ: CLDX) dropped 11.81% to $25.77 on Q4 results. Celldex posted a Q4 loss of $0.27 per...
StreetInsider.com  Mar 3  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Akorn%2C+Inc.+%28AKRX%29+Reports+In-Line+Q4+EPS%3B+Guides+FY14+EPS%2C+Revs/9234439.html for the full story.
Benzinga  Feb 21  Comment 
Below are the top drugs-generic stocks on the NASDAQ in terms of return on equity. The trailing-twelve-month return on equity at Akorn (NASDAQ: AKRX) is 20.78%. Akorn's revenue for the same period is $304.28 million. The...
DailyFinance  Jan 9  Comment 
Akorn, Inc. (NASDAQ: AKRX), a niche generic pharmaceutical company, today announced that it has acquired the NDA and all rights to Betimol® (timolol ophthalmic solution) 0.25% & 0.5% from Santen. Akorn plans to begin shipping...
FiercePharma  Jan 6  Comment 
What's a departing CEO worth after a merger? Not $85 million, according to nearly 5 million Hi-Tech Pharmacal shareholders. But while an advisory vote revealed that many investors were less than enthused with CEO David Seltzer's golden parachute,...
Market Intelligence Center  Dec 17  Comment 
After Monday’s trading in Akorn Inc. (AKRX) the algorithms behind MarketIntelligenceCenter.com's Artifical Intelligence Center picked out a trade that offers a 4.12% or 8.08% (for comparison purposes only), while providing 11.65% downside...





You may also be interested in articles related to Akorn (AKRX):
 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki